1
|
Minga I, Kwak E, Hussain K, Wathen L, Gaznabi S, Singh L, Macrinici V, Wang CH, Singulane C, Addetia K, Sarswat N, Slivnick J, Pursnani A. Prevalence of valvular heart disease in cardiac amyloidosis and impact on survival. Curr Probl Cardiol 2024; 49:102417. [PMID: 38280494 DOI: 10.1016/j.cpcardiol.2024.102417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 01/18/2024] [Indexed: 01/29/2024]
Abstract
BACKGROUND Limited data exists on the prognostic impact of valvular heart disease in cardiac amyloidosis (CA). We therefore sought to define the prevalence of valvular disease in patients with CA and assess the effects of significant valve disease on survival. METHODS This multi-center retrospective cohort study included consecutive patients with confirmed transthyretin (TTR) or light chain (AL) amyloidosis. Echocardiographic data closest to the date of amyloid diagnosis was reviewed, and severity was graded according to ASE guidelines. Kaplan-Meier survival analysis was performed to compare survival between patients with moderate or greater valve disease against those with mild or less disease. RESULTS We included 345 patients (median age 76 years; 73 % men; 110 AL, 235TTR). The median survival for the total patient cohort with cardiac amyloidosis was 2.92 years, with 30 % of patients surviving at five years after their diagnosis. Median survival comparing AL vs ATTR was 2.58 years vs 2.82 years (p = 0.67) The most common valvular abnormalities in the total cohort were mitral (62 %) and tricuspid (66 %).regurgitation There was a statistically significant difference in median survival between patients with no or mild MR compared to those with moderate or severe MR (2.92 years vs 3.35 years, p = 0.0047) (Fig. 5). There was a statistically significant difference in median survival in patients with no or mild TR compared to those with moderate or severe TR (3.35 years vs 2.3 years, p = 0.015). CONCLUSION Our study demonstrates a significant prevalence of mitral and tricuspid regurgitation in CA, with patients with moderate to severe MR and TR having a poorer prognosis.
Collapse
Affiliation(s)
- Iva Minga
- University of Chicago Medical Center, Chicago, IL, United States.
| | - Esther Kwak
- Medical College of Milwaukee Medical Center, Milwaukee, IL, United States
| | - Kifah Hussain
- Northshore University HealthSystem, Evanston, IL, United States
| | - Lucas Wathen
- Northshore University HealthSystem, Evanston, IL, United States
| | | | - Lavisha Singh
- Northshore University HealthSystem, Evanston, IL, United States
| | | | - Chi-Hsiung Wang
- Northshore University HealthSystem, Evanston, IL, United States
| | | | - Karima Addetia
- University of Chicago Medical Center, Chicago, IL, United States
| | - Nitasha Sarswat
- University of Chicago Medical Center, Chicago, IL, United States
| | - Jeremy Slivnick
- University of Chicago Medical Center, Chicago, IL, United States
| | - Amit Pursnani
- Northshore University HealthSystem, Evanston, IL, United States
| |
Collapse
|
2
|
Minga I, Hussain K, Wathen L, Singh L, Lee K, Balasubramanian S, Pursnani A, Sarswat N. HIGH SENSITIVITY TROPONIN AND PRO-BNP IN PREDICTING OUTCOMES IN A COMMUNITY-BASED COHORT OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)01083-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
3
|
Hussain K, Minga I, Lee K, Wathen L, Singh L, Wang CH, Shetty M, Rosenberg JR, Levisay JP, Karagodin I, Liebelt J, Ricciardi MJ, Pursnani A. CTA/CT-FFR FOR CAD ASSESSMENT PRE-TAVR AND RATE OF DOWNSTREAM INVASIVE ANGIOGRAPHY AND COMPLICATIONS. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)01871-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
4
|
Hussain K, Macrinici V, Wathen L, Balasubramanian SS, Minga I, Gaznabi S, Kwak E, Wang CH, Iqbal SH, Pursnani A, Sarswat N. Impact of Tafamidis on Survival in a Real World Community-Based Cohort. Curr Probl Cardiol 2022; 47:101358. [PMID: 35995245 DOI: 10.1016/j.cpcardiol.2022.101358] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Accepted: 08/16/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND Tafamidis is the only therapy shown to improve survival in transthyretin cardiac amyloidosis (ATTR) based on randomized controlled trial data. OBJECTIVES We sought to evaluate the impact of tafamidis on survival in a real-world community based cohort. METHODS This was a prospective observational cohort study that included consecutive patients with confirmed ATTR based on biopsy or TcPYP imaging. Baseline characteristics were compared between patients taking tafamidis versus not, and Kaplan-Meier survival analysis was performed to compare survival between these groups. We examined the reasons that ATTR patients were not on tafamidis. RESULTS Of 107 ATTR patients, median age was 83.9 years, 79% were men, and 63 (59%) of them were on tafamidis. Demographics and baseline cardiovascular risk factors did not differ significantly between those on versus off tafamidis, although there was a higher proportion of NYHA Class III or IV heart failure in those off tafamidis (76% vs 57%, p<.01). The most common reasons patients were not on tafamidis included delays in obtaining the drug or financial barriers (59%) and NYHA Class IV heart failure (19.5%). Patients taking tafamidis had a significantly higher median survival compared to those not on tafamidis (median survival 6.70 vs 1.43 years, p<.0001). CONCLUSIONS Our study demonstrates significantly improved survival in ATTR patients taking tafamidis. Barriers exist to tafamidis initiation including delayed access and affordability, and efforts should be made to improve patient access.
Collapse
Affiliation(s)
- Kifah Hussain
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois.
| | - Victor Macrinici
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | - Lucas Wathen
- Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | - Senthil S Balasubramanian
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | - Iva Minga
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | - Safwan Gaznabi
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | - Esther Kwak
- Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | - Chi-Hsiung Wang
- Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois
| | | | - Amit Pursnani
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois; University of Chicago Pritzker School of Medicine, Chicago
| | - Nitasha Sarswat
- NorthShore University HealthSystem, Evanston, Illinois; Department of Cardiology, NorthShore University HealthSystems, Evanston, Illinois; University of Chicago Pritzker School of Medicine, Chicago
| |
Collapse
|
5
|
Prodromos CC, Finkle S, Prodromos A, Chen JL, Schwartz A, Wathen L. Treatment of Rotator Cuff Tears with platelet rich plasma: a prospective study with 2 year follow-up. BMC Musculoskelet Disord 2021; 22:499. [PMID: 34051761 PMCID: PMC8164813 DOI: 10.1186/s12891-021-04288-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 04/21/2021] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Surgical treatment of full-thickness rotator cuff (RC) tears is associated with generally good results. There is no consensus regarding treatment of partial thickness tears that fail conservative treatment. The purpose of this study was to look at the efficacy and confirm the safety of dual injection PRP into the shoulder of patients with rotator cuff pathology who have failed conservative treatment with followup to two years. METHODS Seventy-one shoulders with MRI confirmed, rotator cuff pathology who failed conservative treatment, had dual PRP injection into the rotator cuff. Global improvement, Quick DASH and VAS scores were collected at 6, 12, and 24 months after treatment and comparison of means was used to analyze changes. RESULTS No adverse events were seen in any patient. Based on global rating scores positive results were seen in 77.9 % of patients at 6 months, 71.6 % at 1 year, and 68.8 % of patients at 2 years. Mean VAS scores improved from 50.2 [CI 44.4-56.0] pre-injection to 26.2 [CI 19.5-32.9] at 6 months, 22.4[CI 16.1-28.7] at 1 year and 18.2 [CI 12.3-24.1] at 2 years (p < 0.0001 for all). The mean Q- DASH scores (0-100, 100 worse) improved from 39.2 [CI 34.3-44.1] for all patients before treatment to 20.7[CI 15.0-26.4] at 6 months, 18.0[CI 12.9-23.1] at 1 year, and 13.8 [CI 8.4-18.8] at 2 years (p < 0.0001 for all). No patient with partial tear had clinical evidence of progression to full thickness tear. When separated into subgroups based on rotator cuff status, all subgroups showed improvement. Patients in the > 50 % partial tear group had the best overall improvement based on Global Rating scores while those in the tendinitis group had the poorest outcomes. CONCLUSIONS PRP injection is a safe and effective treatment for RC cuff injury in patients who have failed conservative treatment of activity modification and physical therapy without deterioration of results two years after treatment. Better results are obtained with greater structural tendon damage than in shoulders with inflammation without structural damage. TRIAL REGISTRATION This is not a clinical trial.
Collapse
Affiliation(s)
- Chadwick C Prodromos
- Illinois Sportsmedicine and Orthopaedic Centers, 1714 Milwaukee Ave, 60025, Glenview, IL, USA.
| | - Susan Finkle
- Illinois Sportsmedicine and Orthopaedic Centers, 1714 Milwaukee Ave, 60025, Glenview, IL, USA
| | - Alexandra Prodromos
- Illinois Sportsmedicine and Orthopaedic Centers, 1714 Milwaukee Ave, 60025, Glenview, IL, USA
| | - Jasmine Li Chen
- Illinois Sportsmedicine and Orthopaedic Centers, 1714 Milwaukee Ave, 60025, Glenview, IL, USA
| | - Aron Schwartz
- Illinois Sportsmedicine and Orthopaedic Centers, 1714 Milwaukee Ave, 60025, Glenview, IL, USA
| | - Lucas Wathen
- Illinois Sportsmedicine and Orthopaedic Centers, 1714 Milwaukee Ave, 60025, Glenview, IL, USA
| |
Collapse
|
6
|
Wong S, Yan L, Wathen L, Cauchon N, Ingram M, Chang D, Rosen L. Predictive value of using beagle dog in assessing relative bioavailability between solid dosage formulations of AMG 706 in patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Wong
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - L. Yan
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - L. Wathen
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - N. Cauchon
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - M. Ingram
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - D. Chang
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - L. Rosen
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| |
Collapse
|
7
|
Rosen L, Kurzrock R, Jackson E, Wathen L, Parson M, Eschenberg M, Mulay M, Purdom M, Yan L, Herbst RS. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3013] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Rosen
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - R. Kurzrock
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - E. Jackson
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - L. Wathen
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - M. Parson
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - M. Eschenberg
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - M. Mulay
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - M. Purdom
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - L. Yan
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| | - R. S. Herbst
- John Wayne Cancer Institute, Santa Monica, CA; M.D. Anderson Cancer Ctr, Houston, TX; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
8
|
Yan L, Wong S, Wathen L, Chang D, Ni L, Ingram M, Parson M, Rosen L. The pharmacokinetic (PK) effect of AMG 706 on CYP3A activity evaluated by use of oral midazolam as probe in patients with advanced solid tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3178] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Yan
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - S. Wong
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - L. Wathen
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - D. Chang
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - L. Ni
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - M. Ingram
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - M. Parson
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| | - L. Rosen
- Amgen Inc., Thousand Oaks, CA; John Wayne Cancer Institute, Santa Monica, CA
| |
Collapse
|
9
|
Gilliam BL, Dyer JR, Fiscus SA, Marcus C, Zhou S, Wathen L, Freimuth WW, Cohen MS, Eron JJ. Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:54-60. [PMID: 9215655 DOI: 10.1097/00042560-199705010-00009] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
HIV-1 infection continues to spread worldwide, primarily through sexual intercourse. Because semen is a major vehicle for transmission of HIV-1, we evaluated the effects of reverse transcriptase inhibitor therapy on the amount of HIV-1 in semen. The semen and blood of 11 HIV-1-infected men (i.e. treatment group) were collected before the initiation of reverse transcriptase inhibitor therapy and then 8 to 18 weeks after initiation of therapy. The semen and blood of another 11 HIV-1-infected men (i.e., longitudinal group), who were not on or had no change in antiretroviral therapy for at least 2 months before study entry, were collected at approximately 2-week intervals for 10 to 26 weeks. In the treatment group, 82% of the seminal plasma HIV-1 RNA levels decreased from baseline after 8 to 18 weeks of therapy (median reduction of 1.01 log10, p = 0.01), and 100% of the blood plasma RNA levels decreased from baseline over the same period (median reduction of 0.92 log10, p = 0.003). Five of these patients were followed for at least 52 weeks and had a median seminal plasma HIV-1 RNA level of 0.66 log10 below baseline at 1 year. All subjects in the treatment group with positive cultures at baseline (50%) had negative cultures or a lower infectious units per ejaculate at the 8- to 18-week follow-up examinations. The HIV-1 RNA levels in blood and semen of the longitudinal group did not change significantly over 10 to 26 weeks. Initiation of reverse transcriptase inhibitor therapy effectively reduces shedding of HIV-1 in semen and may therefore reduce the spread of infection within populations.
Collapse
Affiliation(s)
- B L Gilliam
- Department of Medicine, University of North Carolina, Chapel Hill, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Davey RT, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL, Lane HC. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1996; 40:1657-64. [PMID: 8807058 PMCID: PMC163391 DOI: 10.1128/aac.40.7.1657] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human immunodeficiency virus type 1. In the present phase I/II study we evaluated the safety, toxicity, pharmacokinetics, and antiretroviral activities of two-drug and three-drug combinations of DLV and conventional doses of nucleoside analogs compared with those of both DLV monotherapy and two-drug nucleoside analog therapy. A total of 85 human immunodeficiency virus type 1 infected patients with CD4 counts of 100 to 300 cells per mm3 were enrolled in two periods: in the first period patients were randomized to receive either zidovudine (ZDV) plus didanosine (group 1) or ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of DLV (group 2). In the second period, patients were randomized to receive either 1,200 mg of DLV alone per day (group 3) or ZDV plus 1,200 mg of DLV per day (group 4). DLV demonstrated good oral bioavailability at all five doses tested. The major toxicity was a transient mild rash which appeared in 44% of all DLV recipients. Overall, group 2 patients demonstrated more sustained improvements in CD4 counts, percent CD4 cells, branched DNA levels, p24 antigen levels, and virus titers in plasma than group 1, 3, or 4 patients. The magnitude of the response correlated with the intensity of prior nucleoside analog treatment, the non-syncytium-inducing or syncytium-inducing viral phenotype at baseline, and the presence of a wild-type codon at amino acid position 215 in the baseline reverse transcriptase genotype. Despite a transient rash, DLV therapy was well tolerated. Combination therapy with DLV and nucleoside analogs appears promising, with the three-drug combination appearing to be more potent that either two-drug combinations or monotherapy.
Collapse
Affiliation(s)
- R T Davey
- National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Davey RT, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, Cox SR, Polis MA, Kovacs JA, Falloon J. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994; 170:1180-8. [PMID: 7963711 DOI: 10.1093/infdis/170.5.1180] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Single and multiple doses of sCD4-PE40, a soluble recombinant fusion toxin selectively toxic to gp120-expressing cells, were evaluated in persons infected with human immunodeficiency virus type 1 (HIV-1). Seventeen of 24 patients who completed a single-dose safety trial were given either 1, 5, 10, or 15 micrograms/kg of sCD4-PE40 by intravenous bolus once a month for 2 months, then weekly for 6 weeks. The weekly maximally tolerated dose was 10 micrograms/kg. The major toxicity was a transient dose-dependent elevation in hepatic aminotransferases peaking 48 h after infusion. Anti-Pseudomonas exotoxin antibody developed in 58% of recipients, and sera from 13 of 17 showed neutralizing activity against sCD4-PE40. No consistent changes in immunologic or virologic markers were observed. Weekly infusions of < or = 10 micrograms/kg of sCD4-PE40 are generally well tolerated, but additional studies correlating optimal dosing and frequency of administration with efficacy will be needed to define the role of this novel agent in the management of HIV-1-infected patients.
Collapse
Affiliation(s)
- R T Davey
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Cronan CJ, Wathen L. Release of patient medical records. J Ky Med Assoc 1991; 89:14-7. [PMID: 1995751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|